Zymeworks (ZYME) Share-based Compensation (2021 - 2026)
Zymeworks recorded quarterly Share-based Compensation of $6.9 million in Q1 2026, down 21.64% quarter-over-quarter from $8.8 million in Q4 2025, and up 8.33% year-over-year from $6.4 million in Q1 2025.
Zymeworks' Share-based Compensation history runs 6 years deep, the most recent figure standing at $6.9 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 8.33% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $28.6 million (up 38.39% YoY), while the FY2025 annual figure was $28.0 million, up 57.57% from the prior year.
- Share-based Compensation came in at $6.9 million for Q1 2026 at Zymeworks, down from $8.8 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $8.8 million in Q4 2025 to a low of -$8.2 million in Q1 2022.
- A 5-year average of $3.8 million and a median of $4.6 million in 2024 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation tumbled 87.32% in 2023 and jumped 1141.14% in 2024, its largest moves.
- Zymeworks' Share-based Compensation stood at $4.5 million in 2022, then slipped by 25.08% to $3.4 million in 2023, then jumped by 48.99% to $5.0 million in 2024, then jumped by 76.26% to $8.8 million in 2025, then declined by 21.64% to $6.9 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $6.9 million, $8.8 million, and $6.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Zymeworks | 1.84 Bn | 1.47 Bn | - | 6.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.94 Mn |
| Mar 31, 2026 | 6.94 Mn |
| Dec 31, 2025 | 8.85 Mn |
| Dec 31, 2025 | 8.85 Mn |
| Sep 30, 2025 | 6.91 Mn |
| Sep 30, 2025 | 6.91 Mn |
| Jun 30, 2025 | 5.87 Mn |
| Jun 30, 2025 | 5.87 Mn |
| Mar 31, 2025 | 6.40 Mn |
| Mar 31, 2025 | 6.40 Mn |
| Dec 31, 2024 | 5.02 Mn |
| Dec 31, 2024 | 5.02 Mn |
| Sep 30, 2024 | 4.66 Mn |
| Sep 30, 2024 | 4.66 Mn |
| Jun 30, 2024 | 4.56 Mn |
| Jun 30, 2024 | 4.56 Mn |
| Mar 31, 2024 | 3.55 Mn |
| Mar 31, 2024 | 3.55 Mn |
| Dec 31, 2023 | 3.37 Mn |
| Dec 31, 2023 | 3.37 Mn |
| Sep 30, 2023 | 2.04 Mn |
| Sep 30, 2023 | 2.04 Mn |
| Jun 30, 2023 | 367,000.00 |
| Jun 30, 2023 | 367,000.00 |
| Mar 31, 2023 | 2.33 Mn |
| Mar 31, 2023 | 2.33 Mn |
| Dec 31, 2022 | 4.50 Mn |
| Dec 31, 2022 | 4.50 Mn |
| Sep 30, 2022 | 4.80 Mn |
| Sep 30, 2022 | 4.80 Mn |
| Jun 30, 2022 | 2.90 Mn |
| Jun 30, 2022 | 2.90 Mn |
| Mar 31, 2022 | -8.18 Mn |
| Mar 31, 2022 | -8.18 Mn |
| Dec 31, 2021 | -1.69 Mn |
| Dec 31, 2021 | -1.69 Mn |